

# Cristina Sánchez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3079101/publications.pdf>

Version: 2024-02-01

52  
papers

4,916  
citations

136950

32  
h-index

206112

48  
g-index

53  
all docs

53  
docs citations

53  
times ranked

6082  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. <i>Nature Medicine</i> , 2000, 6, 313-319.	30.7	610
2	Towards the use of cannabinoids as antitumour agents. <i>Nature Reviews Cancer</i> , 2012, 12, 436-444.	28.4	303
3	A pilot clinical study of $\delta^9$ -tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. <i>British Journal of Cancer</i> , 2006, 95, 197-203.	6.4	287
4	$\delta^9$ -Tetrahydrocannabinol induces apoptosis in C6 glioma cells. <i>FEBS Letters</i> , 1998, 436, 6-10.	2.8	248
5	Control of the cell survival/death decision by cannabinoids. <i>Journal of Molecular Medicine</i> , 2001, 78, 613-625.	3.9	207
6	$\delta^9$ -Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. <i>Cancer Research</i> , 2006, 66, 6615-6621.	0.9	192
7	Anticancer Mechanisms of Cannabinoids. <i>Current Oncology</i> , 2016, 23, 23-32.	2.2	192
8	Involvement of Sphingomyelin Hydrolysis and the Mitogen-Activated Protein Kinase Cascade in the $\delta^9$ -Tetrahydrocannabinol-Induced Stimulation of Glucose Metabolism in Primary Astrocytes. <i>Molecular Pharmacology</i> , 1998, 54, 834-843.	2.3	189
9	The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. <i>Oncogene</i> , 2011, 30, 245-252.	5.9	160
10	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. <i>Molecular Cancer</i> , 2010, 9, 196.	19.2	156
11	Cannabinoids and cell fate. , 2002, 95, 175-184.		148
12	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. <i>Biochemical Journal</i> , 2002, 363, 183.	3.7	145
13	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. <i>Biochemical Journal</i> , 2002, 363, 183-188.	3.7	144
14	Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55. <i>Molecular Endocrinology</i> , 2011, 25, 1835-1848.	3.7	140
15	Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. <i>Biochemical Pharmacology</i> , 2018, 157, 285-293.	4.4	126
16	Ceramide: a new second messenger of cannabinoid action. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 19-22.	8.7	115
17	The CB <sub>1</sub> Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan. <i>Molecular Pharmacology</i> , 2001, 59, 955-959.	2.3	98
18	Anandamide Enhances Extracellular Levels of Adenosine and Induces Sleep: An In Vivo Microdialysis Study. <i>Sleep</i> , 2003, 26, 943-947.	1.1	98

#	ARTICLE	IF	CITATIONS
19	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	6.3	98
20	Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. Journal of Biological Chemistry, 2014, 289, 21960-21972.	3.4	95
21	Role of Carnitine Palmitoyltransferase I in the Control of Ketogenesis in Primary Cultures of Rat Astrocytes. Journal of Neurochemistry, 1998, 71, 1597-1606.	3.9	88
22	Cannabinoids: A new hope for breast cancer therapy?. Cancer Treatment Reviews, 2012, 38, 911-918.	7.7	88
23	Cannabinoids and Gliomas. Molecular Neurobiology, 2007, 36, 60-67.	4.0	82
24	The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene, 2013, 32, 2534-2542.	5.9	81
25	The Stimulation of Ketogenesis by Cannabinoids in Cultured Astrocytes Defines Carnitine Palmitoyltransferase I as a New Ceramide-Activated Enzyme. Journal of Neurochemistry, 2001, 72, 1759-1768.	3.9	72
26	Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 2004, 47, 315-323.	4.1	70
27	Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. Cell Death and Differentiation, 2015, 22, 131-144.	11.2	70
28	Cannabinoids and ceramide: Two lipids acting hand-by-hand. Life Sciences, 2005, 77, 1723-1731.	4.3	69
29	JunD is involved in the antiproliferative effect of $\delta^9$ -tetrahydrocannabinol on human breast cancer cells. Oncogene, 2008, 27, 5033-5044.	5.9	66
30	Effects of cannabinoids on energy metabolism. Life Sciences, 1999, 65, 657-664.	4.3	63
31	Endocannabinoids and Cancer. Handbook of Experimental Pharmacology, 2015, 231, 449-472.	1.8	45
32	Therapeutic targeting of HER2 <sup>+</sup> CB <sub>2</sub> R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	7.1	40
33	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget, 2016, 7, 47565-47575.	1.8	40
34	$\delta^9$ -Tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Research, 1997, 767, 64-71.	2.2	33
35	Selective, Nontoxic CB <sub>2</sub> Cannabinoid <i>o</i> -Quinone with in Vivo Activity against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2015, 58, 2256-2264.	6.4	33
36	Dopamine DRD2/ANKK1 Taq1A and DAT1 VNTR polymorphisms are associated with a cognitive flexibility profile in pathological gamblers. Journal of Psychopharmacology, 2014, 28, 1170-1177.	4.0	28

#	ARTICLE	IF	CITATIONS
37	Transglycosylation products generated by <i>Talaromyces amestolkiae</i> GH3 $\beta$ -glucosidases: effect of hydroxytyrosol, vanillin and its glucosides on breast cancer cells. <i>Microbial Cell Factories</i> , 2019, 18, 97.	4.0	28
38	Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin $\beta$ -sarcin in nude mice bearing human colorectal cancer xenografts. <i>SpringerPlus</i> , 2015, 4, 168.	1.2	26
39	Loss of Cannabinoid CB <sub>1</sub> Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. <i>Cerebral Cortex</i> , 2017, 27, 5303-5317.	2.9	23
40	Are Cytoskeletal Components Involved in the Control of Hepatic Carnitine Palmitoyltransferase I Activity?. <i>Biochemical and Biophysical Research Communications</i> , 1996, 224, 754-759.	2.1	21
41	Effects of anandamide on hepatic fatty acid metabolism. <i>Biochemical Pharmacology</i> , 1995, 50, 885-888.	4.4	18
42	New Inhibitors of Angiogenesis with Antitumor Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3757-3766.	6.4	18
43	TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling. <i>Molecular and Cellular Oncology</i> , 2015, 2, e980134.	0.7	16
44	Metabolic stimulation of mouse spleen lymphocytes by low doses of 9-tetrahydrocannabinol. <i>Life Sciences</i> , 1997, 60, 1709-1717.	4.3	15
45	Evidence for the Lack of Involvement of Sphingomyelin Hydrolysis in the Tumor Necrosis Factor-Induced Secretion of Nerve Growth Factor in Primary Astrocyte Cultures. <i>Journal of Neurochemistry</i> , 2002, 71, 498-505.	3.9	10
46	In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer. <i>Experimental and Molecular Pathology</i> , 2017, 102, 268-275.	2.1	8
47	Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from <i>Talaromyces amestolkiae</i> : Potential Antiproliferative and Neuroprotective Effect of These Molecules. <i>Antioxidants</i> , 2022, 11, 1325.	5.1	5
48	Genetic diversity of 15 STRs in Choles from northeast of Chiapas (Mexico). <i>Journal of Forensic Sciences</i> , 2005, 50, 1499-501.	1.6	4
49	Signaling at zero g: a comment. <i>Trends in Biochemical Sciences</i> , 2001, 26, 533.	7.5	1
50	The Role of GPR55 in Cancer. , 2013, , 115-133.		1
51	Targeting Cannabinoid Receptors in Brain Tumors. , 2008, , 361-374.		1
52	Ceramide Signaling in Cannabinoid Action. <i>Molecular Biology Intelligence Unit</i> , 2002, , 125-132.	0.2	0